Schedule your appointment or stop by and take the first step
13 , 19932001.e1992 (2015)
Healthcare providers gradually increase the tirzepatide dose to lower the risk of the most common side effects of this drug
Generic manufacturers can begin challenging certain Zepbound patents via whats called a Paragraph IV certification starting in November 2027, but the most important patent for patients seeking the drug for weight loss is the one covering the use of tirzepatide for chronic weight management, which is in place until June 2039
It's a "very infrequent" side effect, according to the company that makes it, but it can be permanent
Some easy messaging shifts include: From low-calorie to nutrient-packed From control cravings to support your journey From guilt-free to made to feel good This new class of drugs isnt a fad or a trend, says IFF, which has developed a series of consumer personas of GLP-1 users with distinct values, health goals and emotional drivers